H.C. Wainwright keeps a Buy rating on Krystal Biotech (KRYS) with a $240 price target after Abeona Therapeutics (ABEO) announced FDA approval of Zevaskyn, an autologous cell-based therapy for treatment of adult and pediatric patients with recessive dystrophic epidermolysis bullosa. The firm does not see an immediate impact of Zevaskyn on Krystal’s Vykuvek commercial opportunity. Vykuvek remains the “differentiated opportunity, particularly with regard to cost, surface area coverage for wound healing and quality of life/convenience,” the analyst tells investors in a research note. Wainwright believes Vykuvek maintains its differentiated profile as the RDEB treatment of choice to both patients and clinicians.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Krystal Biotech’s Promising Future: Buy Rating Backed by EU Approval and Strategic Market Expansion
- Krystal Biotech price target raised to $240 from $221 at H.C. Wainwright
- Krystal Biotech’s European Approval and Gene Therapy Advancements Drive Buy Rating
- Krystal Biotech Gains EU Approval for VYJUVEK®
- Krystal Biotech announces EC approval of VYJUVEK
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue